GlassScriptPhysician profile
Joseph A Gallagher
NPI 1588759625
$2,609.61
in general payments reported to CMS, 2019-2025
24 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $893 · 2022: $209 · 2023: $620 · 2024: $745 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,487 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,486.95 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $410.40 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $371.43 | 2021-2025 | Freestyle Libre |
| Astrazeneca Pharmaceuticals LP | $312.28 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $253.12 | 2021-2025 | Rybelsus, Ozempic |
| Dexcom, INC. | $138.00 | 2021-2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $123.75 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $118.82 | 2021-2024 | Dificid, Pifeltro, Delstrigo |
| Amgen INC. | $116.31 | 2021-2023 | Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.27 | 2021-2025 | Jardiance |
| Insulet Corporation | $99.51 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.75 | 2021-2025 | |
| Pfizer INC. | $75.42 | 2021-2024 | |
| Axsome Therapeutics, INC. | $60.39 | 2023 | Auvelity |
| Janssen Pharmaceuticals, INC | $49.43 | 2021 | |
| Vanda Pharmaceuticals INC. | $39.84 | 2024 | Hetlioz, Fanapt |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $39.81 | 2021-2023 | Tymlos |
| Viiv Healthcare Company | $39.63 | 2021 | |
| Exact Sciences Corporation | $36.69 | 2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.31 | 2023-2024 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $24.69 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $20.32 | 2024 | Austedo Xr |
| Shield Therapeutics INC | $20.05 | 2024 | |
| Amryt Pharma Holdings LTD | $18.11 | 2021 | |
| Amarin Pharma, INC. | $17.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Gallagher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.